| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7b72691b61448140b9a080282c2ccf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a74935159a0a871dd85e00c138f7fe6b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L29-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 |
| filingDate |
2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1214ea6126e22201719e33429b05e79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_880fdc5c9e462accc3295cd34e46f393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39ca42a0f3eeba4621a7369292a02323 |
| publicationDate |
2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020121645-A1 |
| titleOfInvention |
Composition for preventing or treating egfr-mutant non-small cell lung cancer |
| abstract |
Disclosed is a composition and method for preventing, ameliorating or treating an EGFR-mutant non-small cell lung cancer including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The composition significantly reduces the level of EGFR in EGFR-mutant non-small cell lung cancer cells, inducing apoptosis. Therefore, the composition is suitable for preventing, ameliorating or treating non-small cell lung cancers in subjects in need thereof. Particularly, the composition is effective in treating and preventing non-small cell lung cancers, which are difficult to effectively treat and prevent with gefitinib or erlotinib. Also disclosed is a composition and method for inhibiting the resistance of a non-small cell lung cancer to an EGFR tyrosine kinase inhibitor including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The inhibitory composition effectively overcomes resistance to EGFR tyrosine kinase inhibitors. |
| priorityDate |
2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |